{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:27:54Z","timestamp":1769722074850,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,17]]},"DOI":"10.7759\/cureus.37727","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:17:12Z","timestamp":1681777032000},"source":"Crossref","is-referenced-by-count":1,"title":["Imatinib-Induced Pleuro-Pericardial Effusion and Atrial Fibrillation: An Unusual Side Effect Following the Treatment of a Rare Gastrointestinal Tumor"],"prefix":"10.7759","author":[{"given":"Neel N","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gashaw","family":"Hassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajid","family":"Siddiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s004280000338","article-title":"Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis","volume":"438","author":"Miettinen M","year":"2001","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001, 438:1-12. 10.1007\/s004280000338","journal-title":"Virchows Arch"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran VP","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, et al.. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011, 17:1094-100. 10.1038\/nm.2438","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib mesylate","volume":"212","author":"Waller CF","year":"2018","unstructured":"Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2018, 212:1-27. 10.1007\/978-3-319-91439-8_1","journal-title":"Recent Results Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229975","article-title":"Imatinib-induced pericardial effusion in a child","volume":"12","author":"Terry C","year":"2019","unstructured":"Terry C, Avery P, Morton S, Aron J. Imatinib-induced pericardial effusion in a child. BMJ Case Rep. 2019, 12:3-7. 10.1136\/bcr-2019-229975","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.194227","article-title":"Imatinib-induced pleural effusion: a case report","volume":"63","author":"Banka R","year":"2017","unstructured":"Banka R, Udwadia Z. Imatinib-induced pleural effusion: a case report. J Postgrad Med. 2017, 63:55-7. 10.4103\/0022-3859.194227","journal-title":"J Postgrad Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen M","year":"2005","unstructured":"Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005, 29:52-68. 10.1097\/01.pas.0000146010.92933.de","journal-title":"Am J Surg Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker BJ","year":"2000","unstructured":"Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000, 105:3-7. 10.1172\/JCI9083","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu H","year":"2001","unstructured":"Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344:1052-6. 10.1056\/NEJM200104053441404","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000487511","article-title":"The story of imatinib in GIST - a journey through the development of a targeted therapy","volume":"41","author":"Reichardt P","year":"2018","unstructured":"Reichardt P. The story of imatinib in GIST - a journey through the development of a targeted therapy. Oncol Res Treat. 2018, 41:472-7. 10.1159\/000487511","journal-title":"Oncol Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601695","article-title":"Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages","volume":"199","author":"Bellora F","year":"2017","unstructured":"Bellora F, Dondero A, Corrias MV, et al.. Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages. J Immunol. 2017, 199:1516-25. 10.4049\/jimmunol.1601695","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2015.16.2.304","article-title":"Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management","volume":"16","author":"Kim KW","year":"2015","unstructured":"Kim KW, Shinagare AB, Krajewski KM, Pyo J, Tirumani SH, Jagannathan JP, Ramaiya NH. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol. 2015, 16:304-13. 10.3348\/kjr.2015.16.2.304","journal-title":"Korean J Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles FJ","year":"2009","unstructured":"Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009, 23:1698-707. 10.1038\/leu.2009.111","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0110-4","article-title":"Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors","volume":"4","author":"Kelly K","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009, 4:99-105. 10.1007\/s11523-009-0110-4","journal-title":"Target Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke CD","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, et al.. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26:626-32. 10.1200\/JCO.2007.13.4452","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: A real-world single-center experience","volume":"98","author":"Novo G","year":"2020","unstructured":"Novo G, Di Lisi D, Bronte E, et al.. Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: A real-world single-center experience. Oncology. 2020, 98:445-51. 10.1159\/000505486","journal-title":"Oncology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00347.x","article-title":"Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib","volume":"74","author":"Breccia M","year":"2005","unstructured":"Breccia M, D'Elia GM, D'Andrea M, Latagliata R, Alimena G. Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib. Eur J Haematol. 2005, 74:89-90. 10.1111\/j.1600-0609.2004.00347.x","journal-title":"Eur J Haematol"},{"key":"ref17","article-title":"Cardiovascular adverse events associated with first, second and third generation tyrosine kinase inhibitors used in treatment of chronic myeloid leukemia","volume":"10","author":"Mahida H","year":"2018","unstructured":"Mahida H, Gharia B, Ugoeke N, Maludum O, Asif A, Calderon D. Cardiovascular adverse events associated with first, second and third generation tyrosine kinase inhibitors used in treatment of chronic myeloid leukemia. Circulation. 2018, 10:1161.","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01058","article-title":"Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms","volume":"9","author":"Yang X","year":"2018","unstructured":"Yang X, Li X, Yuan M, et al.. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018, 9:1058. 10.3389\/fphar.2018.01058","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa J","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, et al.. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006, 27:949-53. 10.1093\/eurheartj\/ehi825","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan R","year":"2016","unstructured":"Santhanakrishnan R, Wang N, Larson MG, et al.. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016, 133:484-92. 10.1161\/CIRCULATIONAHA.115.018614","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/149837-imatinib-induced-pleuro-pericardial-effusion-and-atrial-fibrillation-an-unusual-side-effect-following-the-treatment-of-a-rare-gastrointestinal-tumor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:40Z","timestamp":1707508840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/149837-imatinib-induced-pleuro-pericardial-effusion-and-atrial-fibrillation-an-unusual-side-effect-following-the-treatment-of-a-rare-gastrointestinal-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.37727","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,17]]}}}